Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy

Drugs and Aging

Volumn 10, Issue 1, 1997, Pages 50-58

  Culig, Zoran ^a   Hobisch, Alfred ^a   Hittmair, Anton ^b   Cronauer, Marcus V ^a   Radmayr, Christian ^a   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; ESTROGEN; GESTAGEN; HYDROXYFLUTAMIDE; NILUTAMIDE;

BONE METASTASIS; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR CELL LINE;

EID: 0031035330     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710010-00005     Document Type: Review

References (69)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1993; 43: 7-26
2. Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-7
3. Chang C, Kokontis J, Liao S. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci U S A 1988; 85: 7211-5
4. Tan JA, Joseph DR, Quarmby VE, et al. The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol Endocrinol 1988; 2: 1276-85
5. Trapman J, Klaassen P, Kuiper GGJM, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988; 153: 241-8
6. Tilley WD, Marcelli M, Wilson JD, et al. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 1989; 86: 327-31
7. Jenster G, van der Korput J, van Vroonhoven C, et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991; 5: 1396-404
8. Simental JA, Sar M, Wilson EM. Domain functions of the androgen receptor. J Steroid Biochem Mol Biol 1992; 43: 37-41
9. Husmann DA, Wilson CM, McPhaul MJ, et al. Antipeptide antibodies to two distinct regions of the androgen receptor protein to the nuclei of target cells in the rat and human prostate. Endocrinology 1990; 126: 2359-68
10. Veldscholte J, Berrevoets CA, Brinkmann AO, et al. Antiandrogens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992; 31: 2393-9
11. 2-terminal and steroid-binding domains. J Biol Chem 1993; 268: 19004-12
12. Page MJ, Parker MG. Effect of androgen on the transcription of rat prostatic binding protein genes. Mol Cell Endocrinol 1982; 28: 343-55
13. Rennie P, Bruchovsky N, Leco K, et al. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993; 7: 23-36
14. Riegman P, Vlietstra R, van der Korput J, et al. The promoter of the prostate specific antigen contains a functional androgen responsive element. Mol Endocrinol 1991; 5: 1921-30
15. Riegman P, Vlietstra R, van der Korput J, et al. Identification and androgen regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol 1991; 76: 181-90
16. Murtha P, Tindall DJ, Young C. Androgen induction of a human prostate specific kallikrein hKLK2: characterization of an androgen response element in the 5′promoter region of the gene. Biochemistry 1993; 32: 6459-64
17. Adler AJ, Danielsen M, Robins DM. Androgen specific gene activation via a consensus glucocorticoid response element is determined by interaction with non receptor factors. Proc Natl Acad Sci U S A 1992; 89: 11660-3
18. Perry JE, Tindall DJ. Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line LNCaP. Cancer Res 1996; 56: 1539-44
19. Barrack ER, Tindall DJ. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res 1987; 239: 155-87
20. Klocker H, Culig Z, Hobisch A, et al. Androgen receptor alterations in prostatic carcinoma. Prostate 1994; 25: 266-73
21. Ruizeveld de Vinter JA, Trapman J, Brinkmann AO, et al. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 1990; 161: 329-32
22. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer - comparison of receptor content and response to therapy. Cancer 1991; 67: 3057-64
23. Van der Kwast TH, Schalken J, Ruizeveld de Vinter JA, et al. Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 1991; 48: 189-93
24. Ruizeveld de Vinter JA, Janssen PJA, Sleddens HMEB, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735-46
25. Hobisch A, Culig Z, Radmayr C, et al. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55: 3068-72
26. Hobisch A, Culig Z, Radmayr C, et al. Androgen receptor status of lymph node metastasis from prostatic carcinoma. Prostate 1996; 29: 129-36
27. Kleinerman DI, Troncoso P, Pisters LL, et al. Expression and structure of the androgen receptor in bone metastases of hormone refractory prostate cancer [abstract]. J Urol 1996; 155: 626A
28. Quarmby VE, Beckman WC, Cooke DB, et al. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 1990; 50: 735-9
29. Tilley WD, Wilson CM, Marcelli M, et al. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382-6
30. Culig Z, Klocker H, Eberle J, et al. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993; 22: 11-22
31. Qigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endoer Rev 1995; 16: 271-321
32. Horoszewicz JS, Leoung SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-18
33. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103-15
34. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 17: 534-40
35. Harris SE, Rong Z, Harris MA, et al. Androgen receptor in human prostate carcinoma LNCaP/Adep cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region [abstract]. In: Bell L, editor. Proceedings of the 72nd Annual Meeting of the Endocrine Society: Atlanta (GA). Bethesda (MD): The Endocrine Society, 1990
36. Montgomery BT, Young CYF, Bilhartz DL, et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line. Prostate 1992; 21: 63-73
37. Quarmby VE, Yarbrough WG, Lubahn DB, et al. Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 1990; 5: 1921-30
38. Henttu P, Vihko P. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J Steroid Biochem Mol Biol 1992; 41: 349-60
39. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 1992; 89: 6319-23
40. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541-50
41. Suzuki H, Sato N, Watabe Y, et al. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 759-63
42. Castagnaro M, Yandell DW, Dockhorn Dworniczak B, et al. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh Dtsch Ges Pathol 1993; 77: 119-23
43. Elo JP, Kvist L, Leinonen K, et al. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 1995; 80: 3494-500
44. Evans BAJ, Harper ME, Daniells CE, et al. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996; 28: 162-71
45. Sharief Y, French FS, Mohler JL, et al. The androgen receptor and androgen-independent prostatic carcinoma [abstract]. J Urol 1996; 155: 515A
46. Uchida T, Wang C, Ohori M, et al. Infrequent androgen receptor gene mutations in prostatic cancer [abstract]. J Urol 1996; 155: 624A
47. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54: 2861-4
48. Tilley WD, Buchanan G, Hickey T, et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2: 277-85
49. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-8
50. Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 28: 153-8
51. Klocker H, Kaspar F, Eberle J, et al. Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome. Am J Hum Genet 1992; 50: 1318-27
52. Batch JA, Williams DM, Davies HR, et al. Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome. Hum Mol Genet 1992; 1: 497-503
53. Peterziel H, Culig Z, Stober J, et al. Mutant androgen receptors in prostatic tumors distinguish between amino acid sequence requirements for transactivation and ligand binding. Int J Cancer 1995; 63: 544-50
54. Bubley G, Fenton M, Fertig A, et al. The hormonal sensitivity of androgen receptor (AR) mutations derived from human tumors [abstract]. Cancer Res 1996; 37: 1680A
55. Tan J, Sharief J, Hamil G, et al. Altered ligand specificity of a mutant androgen receptor (AR) in the androgen-dependent human prostate cancer xenograft, CWR-22: comparison with the LNCaP mutant AR [abstract]. J Urol 1996; 155: 340A
56. Culig Z, Skiber J, Gast A, et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect Prev 1996; 20: 68-75
57. Yuan S, Trachtenberg J, Mills GB, et al. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 533: 1304-11
58. Marcelli M, Haidacher J, Plymate SR, et al. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonudeic acid. Endocrinology 1995; 136: 1040-8
59. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-72
60. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408-10
61. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153: 1946-7
62. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Cancer 1995; 76: 1428-34
63. Scher HI, Bentel JM, Buchanan G, et al. Androgen receptor expression in androgen-independent prostate cancer: relation to flutamide withdrawal [abstract]. Cancer Res 1996; 37: 1672A
64. 24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994; 198: 74-80
65. Takahashi H, Furusato M, Allsbrock Jr WC, et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995; 55: 1621-4
66. Kokontis J, Takakura K, Hay N, et al. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566-73
67. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the AR gene and progression of human prostate cancer. Nature Genet 1995; 9: 401-6
68. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994; 54: 5474-8
69. Ikonen T, Palvimo JJ, Kallio PJ, et al. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 1994; 125: 1359-66